An instrument dedicated for modelling of pulmonary radiotherapy. Issue 1 (April 2015)

• Record Type: Journal Article
• Authors: Niezink, Anne G.H.; Dollekamp, Nienke J.; Elzinga, Harriet J.; Borger, Denise; Boer, Eduard J.H.; Ubbels, Jan F.; Woltman-van Iersel, Marleen; van der Leest, Annija H.D.; Beijert, Max; Groen, Harry J.M.; Kraan, Jan; Hiltermann, Thijo J.N.; van der Wekken, Anthonie J.; van Putten, John W.G.; Rutgers, Steven R.; Pieterman, Remge M.; de Hosson, Sander M.; Roenhorst, Anke W.J.; Langendijk, Johannes A.; Widder, Joachim
• Is Part Of: Radiotherapy and oncology. Volume 115:Issue 1(2015:Apr.)
• Page Start: 3
• Page End: 8
• Publication Date: 2015-04
• Subjects: Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2015.03.020
• Languages: English
• ISSNs: 0167-8140

Abstract

<abstract xml:lang="en" abstract-type="author" id="ab005"> <title id="st110">Abstract</title> <sec> <title id="st080">Background and purpose</title> <p id="sp0005">Radiotherapy plays a pivotal role in lung cancer treatment. Selection of patients for new (radio)therapeutic options aiming at improving outcomes requires reliable and validated prediction models. We present the implementation of a prospective platform for evaluation and development of lung radiotherapy (proPED-LUNG) as an instrument enabling multidimensional predictive modelling.</p> </sec> <sec> <title id="st085">Materials and methods</title> <p id="sp0010">ProPED-LUNG was designed to comprise relevant baseline and follow up data of patients receiving pulmonary radiotherapy with curative intent. Patient characteristics, diagnostic and staging information, treatment parameters including full dose–volume-histograms, tumour control, survival, and toxicity are scored. Besides physician-rated data, a range of patient-rated data regarding symptoms and health-related quality-of-life are collected.</p> </sec> <sec> <title id="st090">Results</title> <p id="sp0015">After 18 months of accrual, 315 patients have been included (accrual rate, 18 per month). Of the first hundred patients included, 70 received conformal (chemo)radiotherapy and 30 underwent stereotactic radiotherapy. Compliance at 3 and 6 months follow-up was 96–100% for patient-rated, and 81–94% for physician-rated assessments. For data collection, 0.4 FTE were allocated in a 183 FTE department (0.2%).</p> </sec> <sec> <title id="st095">Conclusions</title> <p id="sp0020">ProPED-LUNG is feasible with high compliance rates and yields a large amount of high quality prospective disease-related, treatment-related, patient- and physician-rated data which can be used to evaluate new developments in pulmonary radiotherapy.</p> </sec> </abstract>